International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 3, March 2025 **ijppr.humanjournals.com** ISSN: 2349-7203

Nanozymes: Enzyme-Mimicking Nanomaterials for Diagnostics and Therapeutics

Taaniya Javalkar[1], Anasuya Patil[2*], Shrikrishna M Naik[3]

Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Rajajinagar, Bengaluru, Karnataka, India-560010

Received: 2025-3-05 Revised: 2025-3-16 Accepted: 2025-3-23

GRAPHICAL ABSTRACT:



Keywords : Nano enzymes, nanozymes in drug delivery, drug targeting, enzyme-mimicking, natural enzymes, stability.

INTRODUCTION:

Nanozymes, that are nanomaterials having inherent enzyme-like catalytic activity, have received a lot of attention in recent times for their prospective applications in biomedicine, particularly pharmaceuticals. These artificial enzymes perform the same function as natural enzymes but have advantages such as high stability, low production costs, and adaptability. These materials are intended to mimic or improve enzymatic functions, offering a reliable and cost-effective alternative to natural enzymes in a variety of applications. Nanozymes were initially discovered in 2007, and since then have transformed the perception of nanomaterials, which were previously assumed to be physiologically inert. In addition to having a high catalytic activity under physiological conditions, nanozymes—a novel and promising generation of artificial enzymes—also have special qualities like dual functionality, multi-enzyme activity, and low-temperature catalysis. Natural enzymes and chemical catalysts may not be able to use nanozymes because of their special properties.

IMPORTANCE OF NANOZYMES:

Nanozymes, or nanomaterials with enzyme-like properties, have attracted a lot of pharmacological interest due to their unique properties and applications. In medicinal applications, nanozymes—a family of nanomaterials with intrinsic enzyme-mimicking catalytic activity—have successfully overcome the limitations of natural enzymes. These synthetic enzymes offer exceptional properties such as stability in demanding conditions, varied activity, cost-effectiveness, and multifunctionality. They are at the forefront of biomedical research because they have the potential to completely transform diagnostic and treatment approaches. In contrast to natural enzymes, they are suitable for a variety of applications, such as drug administration, diagnostics, and treatment, due to their versatility, affordability, and robustness.

CLASSIFICATION OF NANOZYMES:

Nanozymes are nanomaterials with catalytic characteristics like those of enzymes; they are categorised into many categories according to their structure and content. Nanozymes can be divided into three main categories: metal-based, carbon-based, and metal-organic framework (MOF) nanozymes.

1. Metal-Based Nanozymes

Metal-based nanozymes, which resemble natural enzymes like peroxidase, oxidase, and catalase, are made up of transition metals, metal oxides, and metal alloys. Because they can promote surface reactions and electron transport, these nanozymes have outstanding catalytic activity.

Types of Metal-Based Nanozymes

- Metal Oxide Nanozymes
- Noble Metal Nanozymes
- Metal Sulphide Nanozymes

2. Carbon-Based Nanozymes

Carbon-based nanozymes are made up of carbon nanomaterials such as graphene, carbon nanotubes, and fullerenes, which have enzyme-like properties due to their large surface area, stability, and electrical conductivity.

Types of Carbon-Based Nanozymes

- Graphene Oxide (GO) and Reduced Graphene Oxide (rGO)
- Carbon Dots (CDs)
- Fullerenes

3. Metal-Organic Framework (MOF) Nanozymes

MOF nanozymes are hybrid materials made up of metal ions and organic ligands that produce porous structures with variable catalytic characteristics.

Types of MOF Nanozymes

- Zeolitic Imidazolate Frameworks (ZIFs)
- Prussian Blue Analogues (PBAs)
- Porphyrin-Based MOFs

ADVANTAGES OF NANOZYMES IN DRUG DELIVERY:

- **High Stability:** Resistant to denaturation and degradation, maintaining activity in extreme conditions (e.g., high temperature, pH variations).
- **Scalability:** Cost-effective large-scale synthesis enables widespread clinical use.
- **Customizability:** Surface modifications allow precise targeting, controlled release, and enhanced catalytic properties.
- **Cost-Effective:** Cheaper production compared to natural enzyme extraction and purification.
- **Extended Shelf Life:** Longer storage duration without losing efficiency, eliminating the need for refrigeration or preservatives.

The advantages of nanozymes over natural enzymes in several biological applications:

o Ease of Surface Modification: Nanozyme surfaces can be easily modified with various functional groups or biomolecules, allowing for targeted distribution and particular interactions within biological systems. This trait improves their efficacy in therapeutic and diagnostic settings.

o Scalability: Nanozymes may be synthesised in huge quantities while maintaining consistent quality, overcoming the scalability issues associated with natural enzyme production. This element is especially useful for widespread biomedical applications.

o Multifunctionality: It is possible to design nanozymes that have several enzyme-mimicking properties at once. Certain nanozymes, for example, have both catalase-like and peroxidase-like properties, allowing for intricate therapeutic processes including the control of reactive oxygen species along the course of disease treatment.

o Tunable Catalytic Activity: Researchers can change the content, size, and structure of nanozymes to control their catalytic activity. This tunability enables the development of nanozymes with specialised activity adapted to specific biomedical requirements.

Aspect	Natural Enzymes	Nanozymes
Temperature Tolerance	Limited to physiological ranges (~37°C)	Operate efficiently at high temperatures
pH Range	Narrow, optimal range (~6-8)	Broad, spanning acidic to basic ranges
Shelf-Life	Susceptible to denaturation	Long-term stability
Production Cost	High, requiring complex bioprocesses	Low-cost, scalable synthesis

NANOZYME TOXICITY AND BIOCOMPATIBLITY ISSUES

CONCERNS ABOUT TOXICITY:

Material Composition: Nanozymes' inherent characteristics, especially those derived from metals, can affect their toxicity profiles. For example, depending on the particular metal ions they release, some metal-based nanozymes may have cytotoxic effects.
Biodistribution and Accumulation: Unmodified nanozymes tend to build up in organs including the spleen, liver, and lungs, which might reduce their catalytic activity and possibly make them more hazardous.

Morphology and Size: The way that nanozymes interact with biological systems is greatly influenced by their size and shape. Studies have demonstrated that rod-shaped cerium oxide (CeO_2) nanozymes exhibit morphology-dependent cytotoxicity, as evidenced by increased levels of lactate dehydrogenase (LDH) release and tumour necrosis factor-alpha (TNF-α) release when compared to cubic or octahedral forms.

CONCERNS ABOUT BIOCOMPATIBILITY:

Surface Modification: Applying biocompatible polymer coatings or other surface modifications can improve the biocompatibility of nanozymes. These changes might lessen any negative impacts in biological settings and increase their stability.

Behaviour in Vivo: Extensive research on the ADME (absorption, distribution, metabolism, and excretion) of nanozymes is necessary. It is easier to evaluate these pharmacokinetic characteristics' long-term safety and possible effects on human health when one is aware of them.

Immunogenicity: Since unanticipated immune reactions may result in negative consequences, it is essential to assess the immunotoxicity of nanozymes. To guarantee biosafety, systematic research on how they interact with the immune system is required.

STABILITY AND ROBUSTNESS

Extreme temperatures, pH shifts, and extended storage can all cause natural enzymes to become denaturised and lose their action. These restrictions are bypassed by nanozymes, which provide excellent stability and activity under a range of circumstances.

The main benefits of stability for nanozymes:

- **Denaturation Resistance:** Lack of complex protein structures prevents degradation, ensuring function in harsh conditions.

- **Broad Operational Range:** Maintain activity across varying temperatures, pH levels, high salt concentrations, and organic solvents.

- **Extended Shelf Life:** High thermal and chemical stability enables long-term storage, ideal for pharmaceuticals in low-resource areas.

- **Field Applications:** Resilient in diverse environments, making them suitable for point-of-care diagnostics and environmental monitoring.

- **Targeted Drug Delivery:** Surface modifications allow precise drug binding and delivery, enhancing bioavailability and reducing side effects.

- **Enhanced Diagnostics:** Improve biosensing sensitivity, specificity, and stability, aiding disease biomarker detection.

Nanozymes provide exceptional stability and robustness in pharmaceutical and diagnostic applications, addressing the significant drawbacks of natural enzymes. Their lengthy shelf life, cost-effectiveness, and capacity to maintain catalytic activity in adverse conditions make them an essential tool in the creation of robust medicinal and diagnostic instruments.

STABILITY AND SHELF-LIFE OF NANOZYMES:

In many pharmacological and biomedical applications, nanozymes have become a better option than natural enzymes, especially because of their remarkable stability and long shelf life. In contrast to natural enzymes, which are susceptible to denaturation and destruction in harsh or physiological environments, nanozymes continue to exhibit catalytic activity throughout a broad spectrum of environmental factors. For long-term usage in pharmaceuticals, diagnostics, and other biological applications, their inherent durability makes them very appealing.

Stability of Nanozymes

1. Resistance to Denaturation

- Thermal Stability: Function at high temperatures where natural enzymes denature (e.g., iron oxide nanozymes remain active above 80°C).

- pH Stability: Operate across a broad pH range, including acidic (tumor environments) and alkaline conditions (e.g., cerium oxide nanozymes maintain antioxidant activity from pH 3–10).

2. Protease Resistance

- Unlike natural enzymes, nanozymes are non-proteinaceous and resist proteolytic degradation, enhancing their medicinal applications.

3. Environmental Robustness

- Withstand oxidative stress, solvents, and radiation without loss of function.
- Example: Gold nanozymes retain oxidase-like activity even in strong oxidizing environments, ideal for diagnostics and therapy.

Shelf-Life of Nanozymes:

Nanozymes offer significant advantages in storage and longevity, critical parameters for pharmaceutical and diagnostic applications.

1. Extended Shelf Life

- Maintain catalytic activity at room temperature without refrigeration.
- **Example:** Iron oxide nanozymes retain 95% activity for over a year.

2. Resistance to Oxygen & Moisture

- Unlike protein enzymes, nanozymes resist oxidation and humidity, ensuring long-term stability.

3. Formulation Advantages

- Can be embedded in solid matrices or dry powders for portability.
- **Example:** Lyophilized cerium oxide nanozymes retain activity, ideal for field diagnostics.

Implications for Pharmaceuticals:

The stability and shelf-life of nanozymes offer significant benefits for pharmaceutical applications:

Nanozymes, enzyme-mimicking artificial nanoparticles, are transforming the pharmaceutical industry with their stability and versatility. Ideal for injectable therapies, diagnostics, and drug formulations, they withstand extreme temperatures, pH changes, and oxidative stress. Unlike natural enzymes, they require no refrigeration or preservatives, making them cost-effective and practical for diverse medical applications.

Key Features of Nanozymes in Drug Formulations:

1. **Resistance to Denaturation**:

○ Nanozymes retain their catalytic activity even under prolonged storage and stress conditions, unlike natural enzymes that denature easily.

2. **No Refrigeration Required**:

○ Nanozymes do not require cold-chain logistics, significantly reducing storage and transportation costs.

THERAPEUTIC APPLICATIONS:

Therapeutics: Nanozymes are emerging as effective therapeutic agents due to their ability to mimic enzyme activity and catalyse reactions in physiological environments. Key therapeutic applications include antioxidant therapy, antibacterial treatments, and cancer therapy.

- Antioxidant Therapy: Neurodegenerative and cardiovascular diseases are among the many illnesses linked to oxidative stress, which is brought on by an imbalance between the generation of ROS and antioxidant defences. By mimicking the actions of catalase and superoxide dismutase (SOD), cerium oxide nanozymes neutralise ROS and shield cells from oxidative damage.

- Antibacterial activity: Nanozymes with peroxidase-like activity are interesting substitutes for conventional antibiotics, especially when it comes to drug-resistant bacteria, because they can produce ROS in situ, killing pathogens and breaking up biofilms.

- Cancer Therapy: Nanozymes play a critical role in cancer therapy by selectively targeting tumour cells and activating chemotherapeutic agents or generating cytotoxic ROS in tumour microenvironments. ROS Generation in Tumour Cells: Tumours often have acidic and hypoxic microenvironments that can enhance nanozyme activity. For example, iron oxide nanozymes produce ROS in acidic conditions, inducing oxidative stress specifically in cancer cells. Synergistic Chemotherapy: Nanozymes activate chemotherapeutic drugs, such as doxorubicin, in situ, increasing their efficacy while reducing systemic toxicity. Theragnostic: Nanozymes serve dual roles as imaging agents and therapeutic agents, enabling real-time monitoring of tumour progression while delivering treatment.

- **Nanozymes in Injectable Therapeutics:**

Role of Nanozymes:

Injectable therapeutics need formulations that stay stable in liquid form over long periods of storage and transit. Because of their biocompatibility and robustness, nanozymes meet these requirements.

Examples of Injectable Therapeutics:

Cancer Therapy Nanozyme:

Platinum-based nanoparticles Mechanism: In tumour environments, platinum nanozymes produce reactive oxygen species (ROS) selectively, causing oxidative stress and apoptosis in cancer cells. These nanozymes also deliver chemotherapeutic agents, like doxorubicin, to increase therapeutic efficacy. Stability: Injectable formulations of platinum nanozymes stay stable for more than a year without degrading.

NANOZYMES IN DRUG DELIVERY:

Nanozymes' special qualities, including their ability to mimic enzymes, their stability in physiological settings, and their adjustable surface chemistry, have made them a game-changing tool in the field of drug delivery. In addition to reducing side effects, their capacity to target tissues or cells and regulate drug release increases bioavailability.

Drug delivery systems are designed to carry therapeutic drugs to specified areas in the body, guaranteeing optimum efficacy while minimising off-target consequences. Given their versatility, nanozymes have several benefits:

Targeting Capabilities: To bind cell receptors, nanozymes can be modified with ligands, antibodies, or peptides.

Stimuli-Responsive Release: They allow medications to be released under regulated conditions in response to external stimuli like light or magnetic fields or internal ones like pH or ROS.

Synergistic Effects: To improve treatment results, nanozymes frequently combine therapeutic delivery and catalytic activity.

Mechanisms Of Drug Delivery Using Nanozymes:

Targeting properties of nanozymes are essential for increasing therapeutic efficacy and reducing off-target effects, making them adaptable therapeutic tools. The two main targeting techniques that allow for the accurate delivery of nanozymes to tumour tissues are passive targeting and active targeting.

1. Passive Targeting:

Passive targeting uses the increased permeability and retention (EPR) effect to take advantage of the physiological features of tumour tissues, such as their aberrant vasculature and inadequate lymphatic drainage.

Mechanism of the EPR Effect:

Nanoparticles can extravasate and concentrate in the tumour interstitial space due to the wide fenestrations (100–800 nm) and irregular architecture of tumour blood vessels.

Prolonged retention results from poor lymphatic drainage in tumours, which hinders the removal of these nanoparticles.

Nanozymes in Passive Targeting: Nanozymes can be engineered to exploit the EPR effect by optimizing their size, surface charge, and stability, ensuring efficient accumulation in tumour tissues.

Benefits:

-No complicated functionalisation or external ligands are needed.

-A broad variety of solid tumours displaying the EPR effect can benefit from it.

-Reduces systemic toxicity by restricting treatment medicines to tumour tissues.



2. Active Targeting:

The process of functionalising nanozymes with particular ligands that attach to overexpressed receptors on cancer cells is known as active targeting. This method guarantees improved tumour cell uptake and selectivity.

Mechanism: Targeting ligands are affixed to the surface of nanozymes and can be peptides, antibodies, or small molecules. These ligands aid in receptor-mediated endocytosis by identifying and attaching to receptors that are either highly expressed or unique on tumour cells.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 3, March 2025 ijppr.humanjournals.com ISSN: 2349-7203



Feature	Passive Targeting	Active Targeting
Mechanism	Utilizes the EPR effect	Functionalization with ligands for receptor-specific binding
Selectivity	Tumour-specific but less cell-specific	Highly selective for target cell receptors
Complexity	Relatively simple	Requires ligand functionalization
Effectiveness	Effective for solid tumours with EPR effect	Suitable for tumours with specific overexpressed receptors
Examples	Iron oxide nanozymes	Gold nanozymes with folic acid, antibody-functionalized cerium oxide nanozymes

Both passive and active targeting techniques are essential for improving the accuracy and effectiveness of treatments based on nanozymes. Active targeting depends on interactions specific to receptors for accurate delivery, whereas passive targeting uses the natural tumour environment for accumulation. Nanozymes have the potential to completely transform cancer treatment by enhancing therapeutic results and reducing adverse effects, thanks to continuous developments in nanotechnology.

3. Stimuli-Responsive Drug Release:

→ pH-Responsive Release:

The microenvironments of tumours and inflammatory tissues are frequently acidic. Particularly in these circumstances, medicines are released via nanozymes designed with pH-sensitive linkages.
For instance, in acidic tumour settings, iron oxide nanozymes release doxorubicin, raising the local drug concentration.

→ ROS-Responsive Release:

When sick tissues contain high levels of ROS, nanozymes react by releasing medications or catalysing reactions that counteract oxidative stress. For instance, in the presence of ROS, cerium oxide nanozymes produce neuroprotective compounds, offering tailored treatment for neurodegenerative diseases.

SPECIFIC APPLICATIONS IN DRUG DELIVERY:

Nanozymes in Drug Delivery for Neurodegenerative Diseases:

Neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) are distinguished by oxidative stress, inflammation, and increasing neuronal dysfunction. Traditional therapeutic techniques are frequently hampered by issues like the blood-brain barrier (BBB), medication instability, and systemic toxicity. Nanozymes are a promising alternative for medication administration in these circumstances due to their unique features such as antioxidant activity, biocompatibility, and capacity to traverse the BBB.

Key Features of Nanozymes in Neurodegenerative Diseases:

i. Antioxidant Properties:

Overproduction of reactive oxygen species (ROS) is a primary cause of neuronal damage in neurodegenerative disorders.

Nanozymes like cerium oxide (CeO_2) and manganese oxide (MnO_2) mimic natural enzymes like superoxide dismutase (SOD) and catalase, which neutralise ROS and preserve neurones.

ii. Blood-Brain Barrier Penetration:

The BBB prevents most therapeutic drugs from entering the brain. Nanozymes can be designed with surface modifications (for example, PEGylation or conjugation with targeted ligands such as transferrin) to effectively traverse the BBB.
Their small size (<100 nm) and stability enable them to reach the central nervous system (CNS).

iii.Drug Encapsulation and Delivery:

Nanozymes can carry neuroprotective medications and release them in a regulated manner within the brain. They preserve encapsulated pharmaceuticals from degradation, hence increasing bioavailability and therapeutic effects.

Nanozymes in the Treatment of Inflammatory Diseases:

Many inflammatory disorders, including rheumatoid arthritis, inflammatory bowel disease (IBD), and chronic obstructive pulmonary disease (COPD), are typified by an overabundance of pro-inflammatory cytokines and reactive oxygen species (ROS). Systemic problems, illness progression, and tissue damage are all influenced by these factors. By scavenging ROS, modifying cytokine levels, and facilitating targeted medication delivery, nanozymes, with their enzyme-mimicking catalytic capabilities, provide novel approaches to treating inflammation.

Mechanisms of Nanozymes in Alleviating Inflammation:

1. ROS Scavenging

- ROS exacerbate inflammation by causing oxidative stress and tissue damage.
- Nanozymes mimic antioxidant enzymes (glutathione peroxidase, catalase, SOD) to neutralize ROS.
- This protects tissues, reduces oxidative stress, and blocks inflammatory pathways.

2. Targeted Drug Delivery

- Inflammatory tissues exhibit increased vascular permeability, acidic pH, and elevated marker expression.
- Nanozymes exploit these features for precise drug delivery, minimizing systemic side effects.
- Functionalized with ligands (e.g., peptides, antibodies) that bind to overexpressed markers like ICAM-1.
- Respond to stimuli (e.g., enzymatic activity, pH shifts) to release encapsulated anti-inflammatory drugs.

NANOZYMES IN DIAGNOSTICS:

Nanozymes have emerged as transformative diagnostic tools because of their consistent catalytic activity, resilience, and ability to be tailored for specialised applications. These enzyme-mimicking nanomaterials overcome natural enzyme limitations, such as instability and high production costs, while retaining high sensitivity and specificity in biomarker detection.

❖ **Role of Nanozymes in Diagnostics:**

Enzymes are frequently used in diagnostics to catalyse reactions that detect the presence of biomarkers like glucose, cancer markers, or infections. Nanozymes imitate the activity of natural enzymes, making them a stable, cost-effective, and adaptable option. Their catalytic activities, which include peroxidase, oxidase, catalase, and superoxide dismutase-like functions, are used in biosensing technologies.

PATHOGEN DETECTION USING NANOZYMES:

Accurate and timely pathogen identification is critical for disease control and prevention. Nanozymes are becoming more effective instruments for pathogen detection because of their catalytic qualities that mimic those of enzymes. By catalysing processes in the presence of bacterial or viral antigens that result in observable signals, such as colorimetric, fluorescent, or electrochemical outputs, they make sensitive and specific tests possible.

Mechanism of Nanozyme-Based Pathogen Detection:

By simulating natural enzymes such as catalases, oxidases, or peroxidases, nanozymes catalyse reactions that intensify detection signals. The following are part of the detection mechanism:

- Identification of the Target:

Antibodies, aptamers, or molecular recognition components unique to bacterial or viral antigens are used to functionalise nanozymes.

- The process of catalysis:

The nanozyme produces a detectable signal by catalysing the oxidation of a substrate (such as TMB or ABTS in colorimetric assays) upon contacting the target pathogen.

- Amplification of Signals:

Nanozymes' catalytic effectiveness increases the detection signal's sensitivity and makes it possible to identify low pathogen concentrations.

- Measurement of Output:

The pathogen concentration is determined by measuring the signal, which can be colour change, fluorescence, or electrochemical current.

Applications of Nanozymes in Pathogen Detection:

Identification of Bacteria

Toxins or bacterial antigens can be highly sensitively detected using nanozymes.

For instance, Escherichia coli O157:H7 detection

Gold nanoparticles coupled with anti-E. coli antibodies are known as nanozymes.

Mechanism: When $H2O_2$ is present, the gold nanozymes catalyse the oxidation of TMB, giving it a blue hue.

The concentration of E. coli O157:H7 is correlated with the colour intensity.

Sensitivity: 10 CFU/mL is the detection limit.

For instance, finding Salmonella

Iron oxide nanoparticles functionalised with particular aptamers are called nanozymes.

Identifying Viral

By focussing on viral proteins or genetic material, nanozymes make it easier to identify viral infections.

SARS-CoV-2 (COVID-19) is one example.

Nanozyme: Antibodies against the SARS-CoV-2 spike protein functionalise cerium oxide nanoparticles (CeO_2).

Mechanism: When the nanozyme binds to the spike protein, it oxidises a chromogenic substrate, resulting in a signal that can be seen.

As little as 0.1 ng/mL of the spike protein is the detection limit.

For instance, the influenza virus

CHALLENGES ASSOCIATED WITH NANOZYMES:

As synthetic enzyme mimics, nanozymes have attracted a lot of interest because of their potential in environmental, medicinal, and diagnostic applications as well as their durability, affordability, and adaptability. Despite these benefits, there are many obstacles in the way of applying nanozymes from lab research to practical uses. These difficulties include those related to design, synthesis, stability, scalability, biocompatibility, and regulations.

Design and Synthesis Challenges

Complexity of Mimicking Natural Enzymes

Catalytic activity and substrate recognition are made possible by the complex three-dimensional architectures and highly specialized active sites seen in natural enzymes. It is very difficult to mimic such intricacy in nanozymes.

Substrate Specificity: The broad catalytic activity of nanozymes can result in off-target effects or decreased efficiency for particular activities.

Designing active sites with the accuracy of natural enzymes is still a difficult undertaking that calls both sophisticated synthetic and computational techniques.

Scalability of Synthesis

Another significant problem is producing nanozymes at scale while preserving their consistent size, shape, and catalytic capabilities.

Batch Variability: Particle size and catalytic performance can vary depending on the synthesis circumstances.

Cost of Materials: Production costs are raised when costly precursors, like precious metals, are used.

Surface Modification

Enhancing the biocompatibility and specificity of nanozymes requires surface functionalization. It can be difficult to achieve surface alterations that are both stable and effective. Instability: As functional coatings deteriorate, nanozymes' efficacy may be diminished. Complexity: Multistep procedures are frequently used in advanced surface alterations, which raises the production complexity.

Biocompatibility and Toxicity:

Cytotoxicity Concerns:

The inherent chemical characteristics of nanozymes, especially those based on metal or metal oxides, can have cytotoxic consequences.

Metal Ion Release: Ions that disrupt cellular functions may be released by nanozymes like iron oxide or cerium oxide.

Reactive Oxygen Species (ROS): Although they can be beneficial, too much ROS production can harm good cells.

Immunogenicity

Nanozymes have the potential to provoke immune responses, which can present challenges for their use in therapeutic applications.

Protein Corona Development: When nanozymes are introduced into biological environments, they frequently attract and bind to various proteins, forming a "protein corona" on their surface. This protein layer can significantly modify the nanozymes' enzymatic activity and, in some cases, stimulate the immune system, potentially leading to undesired immune reactions.

Stability Challenges:

Long-term Stability:

For nanozymes to be effective, they must retain their catalytic activity and structural integrity both during storage and in practical applications. However, various factors can compromise their stability and performance:

Influence of Environmental Conditions: Nanozymes are sensitive to external environmental factors such as moisture, oxygen, and light. Prolonged exposure to these elements can lead to chemical degradation or physical changes, diminishing their effectiveness and reliability over time.

Tendency to Aggregate: Over time, nanozymes may clump together or aggregate due to intermolecular interactions. This aggregation significantly reduces their surface area and, consequently, their catalytic activity, making them less efficient in their intended applications.

Stability in Biological Environments:

The stability of nanozymes faces additional obstacles when applied under in vivo conditions, where the complex biological environment introduces unique challenges:

Variations in pH Levels: The pH within the human body varies significantly across different tissues, organs, and cellular compartments. These fluctuations can directly influence the catalytic activity and structural stability of nanozymes, potentially reducing their effectiveness in specific locations.

Biodegradation Dynamics: While the biodegradability of nanozymes is often advantageous for ensuring their safe clearance from the body, excessive or rapid degradation can undermine their therapeutic potential. This accelerated breakdown may lead to a loss of catalytic functionality before the nanozymes can fully achieve their intended purpose.

Targeting and Delivery Challenges:

Blood-Brain Barrier (BBB) Penetration:

Nanozymes intended for neurological applications face the significant challenge of crossing the blood-brain barrier (BBB), a highly selective and protective structure that restricts access to the brain.

Role of Size and Surface Charge: To effectively penetrate the BBB, nanozymes must be meticulously designed with specific physical and chemical properties. An optimal size, typically in the range of 10 to 100 nano-meters, is crucial for facilitating their transport across the barrier. Additionally, the surface charge of nanozymes must be carefully optimized to improve their interaction with the BBB, as inappropriate charges can hinder their ability to cross or lead to undesirable interactions.

Incorporation of Targeting Ligands: The functionalization of nanozymes with specific targeting ligands, such as peptides or antibodies, can enhance their ability to bind to receptors expressed on the BBB. This targeted approach improves their likelihood of crossing into the brain tissue. However, while this strategy increases their effectiveness, it also introduces additional complexity into the synthesis and production process, making scalability and consistency more challenging.

Specificity for Target Tissues:

Challenges in Toxicity Evaluation: Assessing the potential toxicity of nanozymes presents a significant challenge, as existing models may not adequately account for their unique characteristics or long-term effects. Unlike traditional drugs, nanozymes can interact with biological systems in diverse and unpredictable ways, influenced by their size, shape, surface properties, and catalytic activity. Current toxicity assessment protocols may fail to capture these interactions comprehensively, leaving gaps in understanding their prolonged impact on human health.

Barriers to Clinical Translation: Despite their promising potential, only a limited number of nanozymes have progressed to clinical trials. This slow advancement can be attributed to the stringent regulatory requirements for demonstrating both safety and efficacy. The multifaceted nature of nanozymes necessitates extensive preclinical testing, which often involves time-intensive and costly studies to meet the high standards set by regulatory agencies. These rigorous demands have slowed the translation of nanozymes from laboratory research to real-world clinical applications.

CONCLUSION:

Nanozymes, enzyme-mimicking nanomaterials, are gaining attention in biomedicine, pharmaceuticals, and diagnostics. They offer superior stability, cost-effectiveness, and adaptability compared to natural enzymes, making them valuable for drug delivery, cancer therapy, and biosensing.

A key advantage is their ability to retain catalytic activity under extreme conditions, unlike natural enzymes prone to denaturation. Their prolonged shelf life and tunable properties enable precision medicine applications. In cancer therapy, nanozymes generate reactive oxygen species (ROS) in tumor microenvironments, selectively killing cancer cells. They also enhance drug delivery by enabling controlled release of chemotherapeutics, improving efficacy while reducing side effects. In biosensing, nanozymes allow for sensitive, cost-effective detection of biomarkers and pathogens, enabling rapid diagnostics.

Beyond healthcare, nanozymes are useful in wastewater treatment, food safety monitoring, and industrial catalysis due to their stability and efficiency.

Challenges remain, including concerns about biocompatibility, toxicity, long-term stability, and immunogenicity. Large-scale synthesis with controlled properties and regulatory approvals must also be addressed. Despite these hurdles, nanozymes have the potential to revolutionize medicine and industry. Further research is essential to optimize their properties, ensure safety, and facilitate clinical translation, ultimately improving patient outcomes and advancing biomedical innovation.

FURTURE PERSPECTIVES:

 Advanced Targeting & Drug Delivery

- Enhanced specificity through ligand functionalization for targeted therapy.
- Improved blood-brain barrier (BBB) penetration for neurodegenerative disease treatment.

 Personalized Medicine & Theranostics

- Patient-specific drug release tailored to disease conditions.
- Real-time monitoring of disease progression alongside targeted treatment.

 Next-Generation Biosensors

- Highly sensitive biosensors for early cancer and infectious disease detection.
- Ultra-low detection limits for accurate and timely diagnoses.

 Sustainable & Biodegradable Nanozymes

- Eco-friendly synthesis to reduce toxicity and environmental impact.

- Development of biodegradable nanozymes for safer applications.

 Clinical Translation & Regulation

- Standardized characterization and rigorous clinical evaluations.
- Overcoming regulatory challenges for mainstream clinical adoption.

 AI & Nanorobotics Integration

- AI-driven optimization of nanozyme properties.
- Autonomous nanorobotics for precise therapeutic interventions.

Acknowledgment: I sincerely express my gratitude to KLE College of Pharmacy, Bengaluru, for providing the necessary resources and support for this review paper. I extend my heartfelt thanks to my guide, Dr. Anasuya Patil, for their invaluable guidance, and to the Head of the Department, Dr H N Shivkumar, for their encouragement. I am also grateful to my teachers and friends for their constant support and motivation throughout this work.

REFERENCES:

1. Gao, L., Zhuang, J., Nie, L., et al. (2007). Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. *Nature Nanotechnology*, 2(9), 577-583.
2. Ren X, Chen D, Wang Y, Li H, Zhang Y, Chen H, Li X, Huo M. Nanozymes-recent development and biomedical applications. Journal of Nanobiotechnology. 2022 Feb 22;20(1):92.
3. Wang X, Guo W, Hu Y, Wu J, Wei H. Nanozymes: next wave of artificial enzymes. Berlin, Heidelberg: Springer; 2016 Jul 27.
4. Lou-Franco J, Das B, Elliott C, Cao C. Gold nanozymes: from concept to biomedical applications. Nano-Micro Letters. 2021 Dec; 13:1-36.
5. Liang M, Yan X. Nanozymes: from new concepts, mechanisms, and standards to applications. Accounts of chemical research. 2019 Jul 5;52(8):2190-200.
6. Wei H, Wang E. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes. Chemical Society Reviews. 2013;42(14):6060-93.
7. Wu J, Wang X, Wang Q, Lou Z, Li S, Zhu Y, Qin L, Wei H. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II). Chemical Society Reviews. 2019;48(4):1004-76.
8. Zhou C, Wang Q, Cao H, Jiang J, Gao L. Nanozybiotics: advancing antimicrobial strategies through biomimetic mechanisms. Advanced Materials. 2024 Aug;36(33):2403362.
9. Zhang R, Jiang B, Fan K, Gao L, Yan X. Designing nanozymes for in vivo applications. Nature Reviews Bioengineering. 2024 Oct;2(10):849-68.
10. Dowding JM, Song W, Bossy K, Karakoti A, Kumar A, Kim A, Bossy B, Seal S, Ellisman MH, Perkins G, Self WT. Cerium oxide nanoparticles protect against Aβ-induced mitochondrial fragmentation and neuronal cell death. Cell Death & Differentiation. 2014 Oct;21(10):1622-32.
11. Huang Y, Ren J, Qu X. Nanozymes: classification, catalytic mechanisms, activity regulation, and applications. Chemical reviews. 2019 Feb 25;119(6):4357-412.
12. Mei L, Zhu S, Liu Y, Yin W, Gu Z, Zhao Y. An overview of the use of nanozymes in antibacterial applications. Chemical Engineering Journal. 2021 Aug 15;418:129431.
13. Cheng C, Wang H, Zhao J, Wang Y, Zhao G, Zhang Y, Liu X, Wang Y. Advances in the application of metal oxide nanozymes in tumor detection and treatment. Colloids and Surfaces B: Biointerfaces. 2024 Jan 24:113767.
14. Yang W, Yang X, Zhu L, Chu H, Li X, Xu W. Nanozymes: activity origin, catalytic mechanism, and biological application. Coordination Chemistry Reviews. 2021 Dec 1;448:214170.
15. Rana SV. Mechanistic paradigms of immunotoxicity, triggered by nanoparticles–a review. Toxicology Mechanisms and Methods. 2024 Dec 4:1-7.
16. Kim N, Jeong YG, Lee S, Kang J, Kim Y, Choi YA, Khang D, Kim SH. Ameliorated Skin Inflammation through the Synergistic Effect of Gold Nanorod–Dexamethasone and Photothermal Therapy. ACS Applied Materials & Interfaces. 2024 Mar 4;16(10):12217-31.
17. Dowding JM, Song W, Bossy K, Karakoti A, Kumar A, Kim A, Bossy B, Seal S, Ellisman MH, Perkins G, Self WT. Cerium oxide nanoparticles protect against Aβ-induced mitochondrial fragmentation and neuronal cell death. Cell Death & Differentiation. 2014 Oct;21(10):1622-32.

18. Xu Q, Zhang Y, Yang Z, Jiang G, Lv M, Wang H, Liu C, Xie J, Wang C, Guo K, Gu Z. Tumor microenvironment-activated single-atom platinum nanozyme with H2O2 self-supplement and O2-evolving for tumor-specific cascade catalysis chemodynamic and chemoradiotherapy. Theranostics. 2022;12(11):5155.
19. Liu Y, Yang Z, Huang X, Yu G, Wang S, Zhou Z, Shen Z, Fan W, Liu Y, Davisson M, Kalish H. Glutathione-responsive self-assembled magnetic gold nanowreath for enhanced tumor imaging and imaging-guided photothermal therapy. Acs Nano. 2018 Jul 12;12(8):8129-37.
20. Das S, Dowding JM, Klump KE, McGinnis JF, Self W, Seal S. Cerium oxide nanoparticles: applications and prospects in nanomedicine. Nanomedicine. 2013 Sep 1;8(9):1483-508.
21. Cao Y, Cheng K, Yang M, Deng Z, Ma Y, Yan X, Zhang Y, Jia Z, Wang J, Tu K, Liang J. Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease. Journal of Nanobiotechnology. 2023 Jan 19;21(1):21.
22. Jiang D, Ni D, Rosenkrans ZT, Huang P, Yan X, Cai W. Nanozyme: new horizons for responsive biomedical applications. Chemical Society Reviews. 2019;48(14):3683-704.
23. Zhang R, Jiang B, Fan K, Gao L, Yan X. Designing nanozymes for in vivo applications. Nature Reviews Bioengineering. 2024 Oct;2(10):849-68.
24. Moradi Hasan-Abad A, Shabankare A, Atapour A, Hamidi GA, Salami Zavareh M, Sobhani-Nasab A. The application of peroxidase mimetic nanozymes in cancer diagnosis and therapy. Frontiers in Pharmacology. 2024 Jan 25;15:1339580.
25. Makkar S, Sarawagi N, Priyadarshi N, Kaul S, Sodhi PK, Srivastava AK, Singhal NK. RECENT ADVANCEMENTS IN NANOZYME HYDROGEL BASED SYSTEM FOR ENHANCED SENSING APPLICATIONS. Biosensors and Bioelectronics: X. 2024 Sep 24:100548.
26. Li X, Hu J, Zhao Q, Yao W, Jing Z, Jin Z. Towards precision medicine: design considerations for nanozymes in tumor treatment. Journal of Translational Medicine. 2024 Nov 16;22(1):1033.
27. Laurentius LB, Owens NA, Park J, Crawford AC, Porter MD. Advantages and limitations of nanoparticle labeling for early diagnosis of infection. Expert Review of Molecular Diagnostics. 2016 Aug 2;16(8):883-95.
28. Tao X, Wang X, Liu B, Liu J. Conjugation of antibodies and aptamers on nanozymes for developing biosensors. Biosensors and Bioelectronics. 2020 Nov 15;168:112537.
29. Niu X, Cheng N, Ruan X, Du D, Lin Y. Nanozyme-based immunosensors and immunoassays: recent developments and future trends. Journal of The Electrochemical Society. 2020;167(3):037508.
30. Wu J, Wang X, Wang Q, Lou Z, Li S, Zhu Y, Qin L, Wei H. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II). Chemical Society Reviews. 2019;48(4):1004-76.
31. Song, Y., Wang, X., Zhao, C., et al. (2010). Nanozyme-based electrochemical biosensors for biomolecule detection. *Analytical Chemistry*, 82(11), 4581–4586.
32. Li S, Zhang Y, Wang Q, Lin A, Wei H. Nanozyme-enabled analytical chemistry. Analytical Chemistry. 2021 Dec 6;94(1):312-23.
33. Gao L, Fan K, Yan X. Iron oxide nanozyme: a multifunctional enzyme mimetic for biomedical applications. Theranostics. 2017;7(13):3207.
34. Gao L, Fan K, Yan X. Iron oxide nanozyme: A multifunctional enzyme mimetics for biomedical application. Nanozymology: Connecting Biology and Nanotechnology. 2020:105-
35. Meng X, Fan K, Yan X. Nanozymes: an emerging field bridging nanotechnology and enzymology. Science China Life Sciences. 2019 Nov;62:1543-6.
36. Wei H, Shang T, Wu T, Liu G, Ding L, Liu X. Construction of an ultrasensitive non-enzymatic sensor to investigate the dynamic process of superoxide anion release from living cells. Biosensors and Bioelectronics. 2018 Feb 15;100:8-15.
37. Zhang W, Yang S, Jiang M, Hu Y, Hu C, Zhang X, Jin Z. Nanocapillarity and nanoconfinement effects of pipet-like bismuth@ carbon nanotubes for highly efficient electrocatalytic CO2 reduction. Nano Letters. 2021 Mar 12;21(6):2650-7.
38. Li X, Klausen LH, Zhang W, Jahed Z, Tsai CT, Li TL, Cui B. Nanoscale surface topography reduces focal adhesions and cell stiffness by enhancing integrin endocytosis. Nano letters. 2021 Aug 4;21(19):8518-26.
39. Ma T, Huang K, Cheng N. Recent advances in nanozyme-mediated strategies for pathogen detection and control. International Journal of Molecular Sciences. 2023 Aug 28;24(17):13342.
40. Yuan J, Duan H, Wang L, Wang S, Li Y, Lin J. A three-in-one hybrid nanozyme for sensitive colorimetric biosensing of pathogens. Food Chemistry. 2023 May 15;408:135212.
41. Zhang R, Jiang B, Fan K, Gao L, Yan X. Designing nanozymes for in vivo applications. Nature Reviews Bioengineering. 2024 Oct;2(10):849-68.
42. Ren X, Chen D, Wang Y, Li H, Zhang Y, Chen H, Li X, Huo M. Nanozymes-recent development and biomedical applications. Journal of Nanobiotechnology. 2022 Feb 22;20(1):92.
43. Zhang X, An Z, An J, Tian X. Bioinspired chiral nanozymes: Synthesis strategies, classification, biological effects and biomedical applications. Coordination Chemistry Reviews. 2024 Mar 1;502:215601.

44. Zhou X, You M, Wang F, Wang Z, Gao X, Jing C, Liu J, Guo M, Li J, Luo A, Liu H. Multifunctional graphdiyne–cerium oxide nanozymes facilitate microRNA delivery and attenuate tumor hypoxia for highly efficient radiotherapy of esophageal cancer. Advanced Materials. 2021 Jun;33(24):2100556.
45. Wang Z, Zeng W, Chen Z, Suo W, Quan H, Tan ZJ. An intratumoral injectable nanozyme hydrogel for hypoxia-resistant thermoradiotherapy. Colloids and Surfaces B: Biointerfaces. 2021 Nov 1;207:112026.
46. Singh S, Dosani T, Karakoti AS, Kumar A, Seal S, Self WT. A phosphate-dependent shift in redox state of cerium oxide nanoparticles and its effects on catalytic properties. Biomaterials. 2011 Oct 1;32(28):6745-53.
47. Zhou X, You M, Wang F, Wang Z, Gao X, Jing C, Liu J, Guo M, Li J, Luo A, Liu H. Multifunctional graphdiyne–cerium oxide nanozymes facilitate microRNA delivery and attenuate tumor hypoxia for highly efficient radiotherapy of esophageal cancer. Advanced Materials. 2021 Jun;33(24):2100556.
48. Wu Q, Kamruzzaman M. Advancements in nanozyme-enhanced lateral flow assay platforms for precision in food authentication. Trends in Food Science & Technology. 2024 Mar 28:104472.
49. Du W, Zhou L, Zhang Q, Liu X, Wei X, Li Y. Inorganic nanomaterial for biomedical imaging of brain diseases. Molecules. 2021 Dec 3;26(23):7340.
50. Nyström AM, Fadeel B. Safety assessment of nanomaterials: implications for nanomedicine. Journal of controlled release. 2012 Jul 20;161(2):403-8.
51. Estevez AY, Pritchard S, Harper K, Aston JW, Lynch A, Lucky JJ, Ludington JS, Chatani P, Mosenthal WP, Leiter JC, Andreescu S. Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia. Free Radical Biology and Medicine. 2011 Sep 15;51(6):1155-63.
52. Carratalá JV, Serna N, Villaverde A, Vázquez E, Ferrer-Miralles N. Nanostructured antimicrobial peptides: The last push towards clinics. Biotechnology advances. 2020 Nov 15;44:107603.
53. Wang X, Hu Y, Wei H. Nanozymes in bionanotechnology: from sensing to therapeutics and beyond. Inorganic Chemistry Frontiers. 2016;3(1):41-60.
54. Boenink M, Swierstra T, Stemerding D. Anticipating the interaction between technology and morality: A scenario study of experimenting with humans in bionanotechnology. Studies in ethics, law, and technology. 2010 Aug 19;4(2).
55. Ameen SS, Omer KM. Metal-organic framework-based nanozymes for water-soluble antioxidants and Total antioxidant capacity detection: Principles and applications. Food Chemistry. 2025 Mar 14:143876.
56. Ahmad F, Wei H. Nanozymes. InNature-Inspired Sensors 2025 Jan 1 (pp. 205-213). Elsevier.
57. Yu Z, Xu Z, Zeng R, Xu M, Zou M, Huang D, Weng Z, Tang D. Tailored Metal–Organic Framework-Based Nanozymes for Enhanced Enzyme-Like Catalysis. Angewandte Chemie. 2025 Feb 10;137(7):e202420200.
58. Guliy OI, Dykman LA. Prospects for the use of nanozyme-based electrochemical and colorimetric sensors for antibiotic detection. Talanta. 2025 May 1;286:127524.
59. Choi D, Jung H, Im J, Yi SY, Kim S, Lee D, Park S, Lee C, Kim J, Han JW, Lee J. Bridging the Catalytic Turnover Gap Between Single-Atom Iron Nanozymes and Natural Enzymes by Engineering the First and Second Shell Coordination. Advanced Materials. 2024 Mar;36(13):2306602.
60. Zhou Y, Liu B, Yang R, Liu J. Filling in the gaps between nanozymes and enzymes: challenges and opportunities. Bioconjugate chemistry. 2017 Dec 20;28(12):2903-9.
61. Ma L, Liang Z, Hou Y, Zhang R, Fan K, Yan X. Nanozymes and Their Potential Roles in the Origin of Life. Advanced Materials. 2025 Feb;37(6):2412211.

How to cite this article:
Anasuya Patil et al. Ijppr.Human, 2025; Vol. 31 (3): 467-482.
Conflict of Interest Statement: All authors have nothing else to disclose.